Global Biosimilars Partnering Terms and Agreements 2010 to 2023
The Global Biosimilars Partnering Terms and Agreements 2010-2023 report provides comprehensive understanding and unprecedented access to the biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.
The Global Biosimilars Partnering Terms and Agreements 2010-2023 report provides an understanding and access to the biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.
- Trends in biosimilars partnering deals
- Disclosed headlines, upfronts, milestones and royalties by stage of development
- Biosimilars partnering contract documents
- Top biosimilars deals by value
The Global Biosimilars Partnering Terms and Agreements 2010-2023 report provides an understanding and access to the biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter biosimilars partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors biosimilars technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest biosimilars, oligonucletides including aptamers agreements announced in the healthcare sectors.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all biosimilars partnering deals announced since 2010 including financial terms where available including over 200 links to online deal records of actual biosimilars partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
For example, analyzing actual company deals and agreements allows assessment of the following:
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What are the precise rights granted or optioned?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
The initial chapters of this report provide an orientation of biosimilars dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in biosimilars dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading biosimilars deals since 2010. Deals are listed by headline value, signed by big pharma, most active biosimilars dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in biosimilars dealmaking with a brief summary followed by a comprehensive listing of biosimilars deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of biosimilars partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 6 lists biosimilars deals by technology type.
In addition, a comprehensive appendix is provided organized by biosimilars partnering company A-Z, deal type definitions and biosimilars partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in biosimilars partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of biosimilars technologies and products.
Report scope
Global Biosimilars Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to biosimilars trends and structure of deals entered into by leading companies worldwide.
Global Biosimilars Partnering Terms and Agreements includes:
- Trends in biosimilars dealmaking in the biopharma industry since 2010
- Access to headline, upfront, milestone and royalty data
- Access to over 200 biosimilars deals
- The leading biosimilars deals by value since 2010
- Most active biosimilars dealmakers since 2010
- The leading biosimilars partnering resources
In Global Biosimilars Partnering Terms and Agreements, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy and technology target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Global Biosimilars Partnering Terms and Agreements provides the reader with the following key benefits:
- In-depth understanding of biosimilars deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Comprehensive access to over 200 actual biosimilars deals entered into by the world’s biopharma companies, together with real world clause examples
- Full listing of biosimilars deals by company A-Z, deal value, phase of development, deal type, and therapy focus
- Identify leading biosimilars deals by value since 2010
- Identify the most active biosimilars dealmakers since 2010
- Detailed access to actual biosimilars contracts enter into by the leading bigpharma
- Insight into the terms included in biosimilars agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in biosimilars dealmaking
2.1. Introduction
2.2. Biosimilars partnering over the years
2.3. Most active biosimilars dealmakers
2.4. Biosimilars partnering by deal type
2.5. Biosimilars partnering by therapy area
2.6. Deal terms for biosimilars partnering
2.6.1 Biosimilars partnering headline values
2.6.2 Biosimilars deal upfront payments
2.6.3 Biosimilars deal milestone payments
2.6.4 Biosimilars royalty rates
Chapter 3 – Leading biosimilars deals
3.1. Introduction
3.2. Top biosimilars deals by value
Chapter 4 – Most active biosimilars dealmakers
4.1. Introduction
4.2. Most active biosimilars dealmakers
4.3. Most active biosimilars partnering company profiles
Chapter 5 – Biosimilars contracts dealmaking directory
5.1. Introduction
5.2. Biosimilars contracts dealmaking directory
Chapter 6 – Biosimilars dealmaking by technology type
Appendices
Appendix 1 – Biosimilars deals by company A-Z
Appendix 2 – Biosimilars deals by stage of development
Appendix 3 – Biosimilars deals by deal type
Appendix 4 – Biosimilars deals by therapy area
Deal type definitions
Further reading on dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Table of figures
Figure 1: Biosimilars partnering since 2010
Figure 2: Active biosimilars dealmaking activity since 2010
Figure 3: Biosimilars partnering by deal type since 2010
Figure 4: Biosimilars partnering by disease type since 2010
Figure 5: Biosimilars deals with a headline value
Figure 6: Biosimilars deals with an upfront value
Figure 7: Biosimilars deals with a milestone value
Figure 8: Biosimilars deals with a royalty rate value
Figure 9: Top biosimilars deals by value since 2010
Figure 10: Most active biosimilars dealmakers since 2010
Pricing options
- $3,995: single-user
- $5,745: multi-user
- $10,995: single site license
- $17,995: global site license
A full explanation of license type definitions can be found here.
Our guarantee
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Delivery Deadline
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
All card payments are processed by SagePay.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
3SBio, 180 Life Sciences, Abbvie, Abreos Biosciences, Abzena, Accord Healthcare, Aceno Biotherapeutics, AdAlta, Advanz Pharma, AET Biotech, Aetos Biologics, AffaMed Therapeutics, Agila Specialties, AIT Bioscience, Algorithme Pharma Holdings, Alteogen, Altiora, Alvogen, Alvotech, Amedica, Amgen, Amneal Pharmaceuticals, Arecor, Avid Bioservices, Axantia, Back-A-Line, Bacterin International, Baxalta, Baxter International, BeiGene, BinnoPharm, Bio-Manguinhos/Fiocruz, Bio-Thera Solutions, Biocnd, Biocon, Bioeq IP, Bio Farma, Biogen, Biooutsource, BiosanaPharma, BioSavita, BioSciencesCorp, Bioton, Bioventure MDC, BioXpress, Blau Pharma, Boehringer Ingelheim, Bolt Biotherapeutics, Boryung Pharmaceutical, Boston Oncology, Bruker, C-Bridge Capital, Catalent, CEA-Leti, Celares, Celerion, Cellectis, Celltrion, Centre for Addiction and Mental Health, Changchun High & New Technology Industries, Chemo Sa Lugano, Chungnam National University, Cipla, CJ Corp, Clinigen, Cobra Biologics, Coherus Biosciences, Compass Biotechnologies, Concord Biosciences, Cook Pharmica, Coya Therapeutics, CR Pharma, Daiichi Sankyo, Diabeloop, DM Corporation, Dong-A Pharmaceutical, Dong-A ST, Dr. Reddy's Laboratories, Dyadic International, EirGenix, EMD Millipore, Enzene Biosciences, Epirus Biopharmaceuticals, Epivax, European Commission, Evercyte, Evotec, Ewopharma, Food and Drug Administration (FDA), Formosa Pharmaceuticals, Formycon, Fujifilm, Fujifilm Kyowa Kirin Biologics, Fuji Pharma, GC Pharma, Gedeon Richter, GE Healthcare, Genentech, Genhelix Biopharmaceutical, Genor Biopharma, GenScript ProBio, Gerresheimer, Hadasit Medical Research Services and Development, Hanwha Chemical, Helvetic Biopharma, Henlius Biotech, Hikma Pharmaceuticals, Hoffmann La Roche, Horizon Europe, Hospira, Innovent Biologics, Intas Pharmaceuticals, inVentiv Health, Ipca Laboratories, Ipsen, Jacobson Pharma, JAMP Pharma Group, JHL Biotech, Kamada, Karolinska Institute, Kemwell BioPharma, Klinge Biopharma, Kymos Pharma Services, Kyowa Hakko Kirin, Laboratorios Liomont, LABORATORIOS SAVAL, Lannett, Ligacept, Livzon Mabpharm, Lupin, M+W Group, Mab-Venture Biopharma, Mabion, Mabwell Bioscience, mAbXience, Medicago, Medicure, Medipolis, Meiji Seika, Merck and Co, Merck BioVentures, Merck KGaA, Merck Serono, MGC Diagnostics, MiGenTra, Minapharm, Mindset Pharma, Ministry of Health (Brazil), Mithra Pharmaceuticals, Mitsubishi Chemical, Mochida Pharmaceutical, Momenta Pharmaceuticals, Mundipharma, Mylan Laboratories, Mylan Pharmaceuticals, Nan Fung Group, NanoLock, Natco Pharmaceuticals, National Cancer Institute, National Comprehensive Cancer Network (NCCN), NCPC GeneTech, Neoletix Biotechnology, NeuClone, Nora Pharma, Novel351k, Novo Nordisk, Ocumension Therapeutics, Oncobiologics, ORF Genetics, Organon, Orox Pharmaceuticals, Orygen Biotecnologia, Pall Corporation, Pangen Biotech, Parexel, PBS Biotech, Perfinity Biosciences, Pfenex, Pfizer, Pharmapark, PharmaPraxis, PlantForm, PlantPraxis Biotecnologia, Polifarma, Polpharma, Portal Instruments, PPD, PRA Health Sciences, Premier Inc, Premier Research, Prestige BioPharma, ProBioGen, PT Etana Biotechnologies, Qilu Pharmaceutical, Quanta BioDesign, QuiaPEG Pharmaceuticals, R-Pharm, Ranbaxy Laboratories, Reliance Life Sciences, Revance Therapeutics, Samsung Bioepis, Samsung Biologics, Sandoz, Sanofi, Santo Holding, Scottish Government, Selexis, Serum Institute of India, Shandong Boan Biological Technology, Shire Pharmaceuticals, Simcere Pharmaceuticals, Similis Bio, SN BioScience, Spectrum Pharmaceuticals, SQI Diagnostics, STADA Arzneimittel, STC Biologics, Stelis Biopharma, Strides Arcolab, Syna Therapeutics, Synthon, TetraLogic Pharmaceuticals, Teva Pharmaceutical Industries, Theradiag, Theramex, Toyota Tsusho, TR-Pharm, True Diagnostics, TS Dyne, Turgut Ilaclari, UGA Biopharma, UMN Pharma, Univercells, University of Illinois, University of Michigan, Vcell Healthcare, Vela Laboratories, Viatris, Viropro, Walloon Region Investment Fund, Walter and Eliza Hall Institute, Watson Pharmaceuticals, Xbrane Bioscience, Xcellerex, Xencor, XL-Protein, Yangtze River Pharmaceutical Group, Yas Holding, YL Biologics, Yoshindo, Ypsomed, Zhejiang Hisun Pharmaceutical, Zhejiang Huahai Pharmaceutical, Zosano Pharma
Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.
The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant
Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.
